Aptevo files prospectus supplement for up to $2,309,834 ATM common-stock offering
On October 30, 2026, Aptevo Therapeutics filed a prospectus supplement under its effective Form S-3 registration statement to sell common stock from time to time with an aggregate offering price of up to $2,309,834 under an existing ATM Sales Agreement. Roth Capital Partners, LLC is the sales agent, and the company reported that it had issued and sold 303,157 shares under the Sales Agreement and Prior Prospectus for $11.8 million in aggregate gross proceeds as of the prospectus supplement date.
Read source-backed brief